{"disease":{"id":"aggressive-b-cell-nhl","name":"aggressive b cell nhl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01994382","title":"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT05583149","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Patrick C. Johnson, MD","has_results":true},{"nct_id":"NCT07059741","title":"Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}